Prime Medicine (PRME) Unveils Strategically Focused Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Citi Reiterates Buy Rating on Prime Medicine (PRME)
September 30, 2024 4:02 PM EDTCiti analyst Samantha Semenkow reiterated a Buy rating and $10.00 price target on Prime Medicine (NASDAQ: PRME).
The analyst comments "This morning, Prime announced a collaboration and licensing agreement with BMS focused on prime edited ex vivo T-cell therapies. The disclosure... More
